临床试验/NCT00819195

NCT00819195已完成不适用

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

University of California, San Francisco1 个研究点分布在 1 个国家目标入组 17 人开始时间: 2008年12月最近更新: 2013年10月8日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: University of California, San Francisco
入组人数: 17
试验地点: 1
主要终点: Production of inflammatory cytokines by monocytes and naive T cells.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Relapsing-remitting (RR) MS patients (McDonald criteria)
•Ages 18-55
•Males and females
•EDSS score ≤5
•No prior treatment with Copaxone
•Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month

排除标准

•Treatment with Tysabri, Novantrone or cyclophosphamide
•Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate)
•Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis
•Pregnancy

研究组 & 干预措施

RRMS

Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care

干预措施: Glatiramer acetate (Drug)

结局指标

主要结局

Production of inflammatory cytokines by monocytes and naive T cells.

时间窗: 0, 1, 2, 4, 6 months

次要结局

未报告次要终点

研究者

发起方

University of California, San Francisco

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Treatment of Multiple Sclerosis With Copaxone and AlbuterolAutoimmune DiseasesMultiple Sclerosis

NCT00039988National Institute of Allergy and Infectious Diseases (NIAID)40

已完成

3 期

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated SyndromeMultiple Sclerosis

NCT00666224Teva Branded Pharmaceutical Products R&D, Inc.481

已完成

3 期

Efficacy and Safety of GTR in Comparison to Copaxone®Multiple Sclerosis

NCT01489254Synthon BV794

已完成

2 期

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid ArthritisArthritis, Rheumatoid

NCT02799472GlaxoSmithKline39

已完成

2 期

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyBrenner TumorFallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPeritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer

NCT00466960University of Washington21